Pancreatic Cancer Research

ResearcherThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteActive in the last 2 years

Ashwini Kumar Esnakula

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6029-0124; OpenAlex author ID A5025576841. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 8

  1. Inferring Clinically Relevant Molecular Subtypes of Pancreatic Cancer from Routine Histopathology Using Deep Learning Co-author DOI 10.21203/rs.3.rs-8545050/v1↗
  2. Inferring Clinically Relevant Molecular Subtypes of Pancreatic Cancer from Routine Histopathology Using Deep Learning Co-author DOI 10.64898/2026.01.06.26343539↗
  3. Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. Co-author DOI 10.3389/fonc.2025.1544928↗
  4. Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy Co-author DOI 10.20944/preprints202409.0945.v1↗
  5. Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. First author DOI 10.3390/ijms25169041↗
  6. Differential Expression and Diagnostic Value of MUC5AC Glycoforms in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers15194832↗
  7. Predictive Value of MUC5AC Signature in Pancreatic Ductal Adenocarcinoma: A Hypothesis Based on Preclinical Evidence. Co-author DOI 10.3390/ijms24098087↗
  8. Understanding the Clinical Impact of MUC5AC Expression on Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/cancers13123059↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ashish Manne · 8 shared papers, 2021–2026 · strength 1.73
  2. Upender Manne · 5 shared papers, 2024–2026 · strength 1.04
  3. Anne M. Noonan · 4 shared papers, 2024–2026 · strength 0.83
  4. Anup Kasi · 4 shared papers, 2023–2025 · strength 0.78
  5. Ravi Kumar Paluri · 4 shared papers, 2023–2025 · strength 0.78
  6. Lianbo Yu · 4 shared papers, 2023–2025 · strength 0.75
  7. Muhammad Khalid Khan Niazi · 2 shared papers, 2026 · strength 0.53
  8. Abdul Akbar · 2 shared papers, 2026 · strength 0.53
  9. Susan Tsai · 2 shared papers, 2026 · strength 0.53
  10. Vaibhav Sahai · 2 shared papers, 2026 · strength 0.53
  11. Kannan Thanikachalam · 3 shared papers, 2024–2025 · strength 0.51
  12. Wancai Yang · 3 shared papers, 2024–2025 · strength 0.51
  13. Ankur Sheel · 3 shared papers, 2024–2025 · strength 0.51
  14. Jordan M. Cloyd · 3 shared papers, 2024–2025 · strength 0.51
  15. Allan Tsung · 2 shared papers, 2021–2023 · strength 0.43
  16. Deepak Sherpally · 2 shared papers, 2024–2025 · strength 0.36
  17. Sameek Roychowdhury · 2 shared papers, 2024 · strength 0.31
  18. Mary E. Dillhoff · 2 shared papers, 2024 · strength 0.31
  19. Aslam M. Ejaz · 2 shared papers, 2024 · strength 0.31
  20. Shafia Rahman · 2 shared papers, 2024 · strength 0.31
  21. Phil A. Hart · 1 shared paper, 2023 · strength 0.24
  22. Timothy Michael Pawlik · 1 shared paper, 2025 · strength 0.21
  23. Laith I. Abushahin · 1 shared paper, 2021 · strength 0.19
  24. Davendra P. S. Sohal · 1 shared paper, 2024 · strength 0.15
  25. Eric David Miller · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.